172 related articles for article (PubMed ID: 12685522)
1. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications.
Swanson JM; Lerner M; Wigal T; Steinhoff K; Greenhill L; Posner K; Freid J; Wigal S
J Atten Disord; 2002; 6 Suppl 1():S73-88. PubMed ID: 12685522
[TBL] [Abstract][Full Text] [Related]
2. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
[TBL] [Abstract][Full Text] [Related]
4. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.
Pelham WE; Gnagy EM; Chronis AM; Burrows-MacLean L; Fabiano GA; Onyango AN; Meichenbaum DL; Williams A; Aronoff HR; Steiner RL
Pediatrics; 1999 Dec; 104(6):1300-11. PubMed ID: 10585981
[TBL] [Abstract][Full Text] [Related]
5. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
6. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
Pelham WE; Gnagy EM; Burrows-Maclean L; Williams A; Fabiano GA; Morrisey SM; Chronis AM; Forehand GL; Nguyen CA; Hoffman MT; Lock TM; Fielbelkorn K; Coles EK; Panahon CJ; Steiner RL; Meichenbaum DL; Onyango AN; Morse GD
Pediatrics; 2001 Jun; 107(6):E105. PubMed ID: 11389303
[TBL] [Abstract][Full Text] [Related]
7. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study.
Auiler JF; Liu K; Lynch JM; Gelotte CK
Curr Med Res Opin; 2002; 18(5):311-6. PubMed ID: 12240794
[TBL] [Abstract][Full Text] [Related]
8. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.
Moen MD; Keam SJ
CNS Drugs; 2009 Dec; 23(12):1057-83. PubMed ID: 19958043
[TBL] [Abstract][Full Text] [Related]
9. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.
Pelham WE; Aronoff HR; Midlam JK; Shapiro CJ; Gnagy EM; Chronis AM; Onyango AN; Forehand G; Nguyen A; Waxmonsky J
Pediatrics; 1999 Apr; 103(4):e43. PubMed ID: 10103335
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
[TBL] [Abstract][Full Text] [Related]
11. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.
Stein MA; Waldman ID; Charney E; Aryal S; Sable C; Gruber R; Newcorn JH
J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):581-8. PubMed ID: 22136094
[TBL] [Abstract][Full Text] [Related]
12. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S
Arch Gen Psychiatry; 2003 Feb; 60(2):204-11. PubMed ID: 12578439
[TBL] [Abstract][Full Text] [Related]
13. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.
Coghill D; Banaschewski T; Zuddas A; Pelaz A; Gagliano A; Doepfner M
BMC Psychiatry; 2013 Sep; 13():237. PubMed ID: 24074240
[TBL] [Abstract][Full Text] [Related]
14. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
Patrick KS; Radke JL; Raymond JR; Koller L; Nguyen LV; Rodriguez W; Straughn AB
Pharmacotherapy; 2019 Jun; 39(6):677-688. PubMed ID: 30351459
[TBL] [Abstract][Full Text] [Related]
15. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
Silva RR; Muniz R; Pestreich L; Brams M; Mao AR; Childress A; Wang J
J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):199-208. PubMed ID: 18176337
[TBL] [Abstract][Full Text] [Related]
16. Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder.
Manos MJ; Short EJ; Findling RL
J Am Acad Child Adolesc Psychiatry; 1999 Jul; 38(7):813-9. PubMed ID: 10405498
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
Quinn D; Wigal S; Swanson J; Hirsch S; Ottolini Y; Dariani M; Roffman M; Zeldis J; Cooper T
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1422-9. PubMed ID: 15502602
[TBL] [Abstract][Full Text] [Related]
18. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
Tuerck D; Wang Y; Maboudian M; Wang Y; Sedek G; Pommier F; Appel-Dingemanse S
Int J Clin Pharmacol Ther; 2007 Dec; 45(12):662-8. PubMed ID: 18184535
[TBL] [Abstract][Full Text] [Related]
19. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
20. Drugs for ADHD.
Med Lett Drugs Ther; 2020 Jan; 62(1590):9-15. PubMed ID: 31999670
[No Abstract] [Full Text] [Related]
[Next] [New Search]
